CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 254 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $245,490 | -13.0% | 21,000 | 0.0% | 0.20% | -21.1% |
| Q2 2023 | $282,240 | -18.9% | 21,000 | 0.0% | 0.26% | -33.2% |
| Q1 2023 | $348,180 | -6.4% | 21,000 | +5.0% | 0.38% | -52.8% |
| Q4 2022 | $372,000 | +44.2% | 20,000 | -0.7% | 0.81% | -11.3% |
| Q3 2022 | $258,000 | +17.3% | 20,145 | -24.0% | 0.92% | +435.1% |
| Q1 2022 | $220,000 | -35.1% | 26,500 | -47.0% | 0.17% | -36.2% |
| Q4 2021 | $339,000 | – | 50,000 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $1,902,000 | 5.68% |
| GABLES CAPITAL MANAGEMENT INC. | 433,814 | $5,566,000 | 4.46% |
| Quantedge Capital Pte Ltd | 503,700 | $6,462,000 | 1.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,896,000 | $62,816,000 | 1.25% |
| Lanham O'Dell & Company, Inc. | 20,145 | $258,000 | 0.92% |
| Capital Impact Advisors, LLC | 59,301 | $907,000 | 0.90% |
| SummerHaven Investment Management, LLC | 98,840 | $1,268,000 | 0.88% |
| Yorktown Management & Research Co Inc | 50,000 | $642,000 | 0.83% |
| GLOBEFLEX CAPITAL L P | 304,293 | $3,904,000 | 0.67% |
| AFFINITY INVESTMENT ADVISORS, LLC | 90,864 | $1,166,000 | 0.60% |